Girolami Jean-Pierre, Bouby Nadine, Richer-Giudicelli Christine, Alhenc-Gelas Francois
INSERM U1138, Centre de Recherche des Cordeliers, 75006 Paris, France.
Rangueil Medical School, Université Paul Sabatier, 31062 Toulouse, France.
Pharmaceuticals (Basel). 2021 Mar 8;14(3):240. doi: 10.3390/ph14030240.
This review addresses the physiological role of the kallikrein-kinin system in arteries, heart and kidney and the consequences of kallikrein and kinin actions in diseases affecting these organs, especially ischemic and diabetic diseases. Emphasis is put on pharmacological and genetic studies targeting kallikrein; ACE/kininase II; and the two kinin receptors, B1 (B1R) and B2 (B2R), distinguished through the work of Domenico Regoli and his collaborators. Potential therapeutic interest and limitations of the pharmacological manipulation of B1R or B2R activity in cardiovascular and renal diseases are discussed. This discussion addresses either the activation or inhibition of these receptors, based on recent clinical and experimental studies.
本综述阐述了激肽释放酶-激肽系统在动脉、心脏和肾脏中的生理作用，以及激肽释放酶和激肽在影响这些器官的疾病（尤其是缺血性疾病和糖尿病）中的作用后果。重点介绍了针对激肽释放酶、血管紧张素转换酶/激肽酶II以及通过多梅尼科·雷戈利及其合作者的研究而区分出的两种激肽受体B1（B1R）和B2（B2R）的药理学和遗传学研究。讨论了在心血管疾病和肾脏疾病中对B1R或B2R活性进行药理学调控的潜在治疗意义和局限性。基于最近的临床和实验研究，本次讨论涉及了这些受体的激活或抑制。
